European Nephrologists Lead the Way with Adoption of Astellas/FibroGen's HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds

/PRNewswire/ -- The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel...

Related Keywords

Germany ,Italy ,United Kingdom ,France ,Spain ,Astellas Fibrogen ,Denise Foy ,National Institute For Health ,United Kingdom National Institute For Health ,European Medicines Agency ,Drug Administration ,National Institute ,Care Excellence ,Realtime Dynamix ,Renal Anemia ,Realworld Dynamix ,Time Dynamix ,World Dynamix ,Global Insights ,Nephrology Franchise ,Spherix Global Insights ,